$PASG

Lynx1 Capital Management LP purchased $206K of PASG (indirect holdings)

Lynx1 Capital Management LP purchased 50,055 indirectly-held shares of Passage BIO, Inc. (PASG) at $4.12 ($0.21M total) on 2026-06-25.

Original reporting
SEC EDGAR · Lynx1 Capital Management LP
Published Jun 29, 2026, 8:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 29, 2026, 8:36 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$PASG
Bullish
medium confidence
Mentioned
$PASG
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PASGBullishLow
01

Why it matters

The newest fact is Lynx1 Capital Management LP’s open-market purchase of 50,055 shares at $4.1175, bringing holdings to 673,759 shares (indirect).

02

Market read

Traders may treat the filing as a small sentiment input, but it does not replace fundamental catalysts (earnings, guidance, trials, deals).

03

What to watch

No 10b5-1 plan and the transaction is indirect; without context on prior buys/sells or total position changes, signal strength is limited.

Relevance 5/10Novelty 5/10Timing: filed 2026-06-29 after-hours; reflects 2026-06-25 purchase

Background

The article is an SEC Form 4 insider transaction disclosure for Passage BIO, Inc. (PASG).

Company-level read

Ticker impact

$PASGBullishMedium confidence
Context

Passage BIO disclosed via Form 4 that Lynx1 Capital Management LP bought 50,055 shares of PASG at $4.1175 on 2026-06-25.

Expected impact

Likely limited near-term impact; any effect would be incremental and fade unless followed by additional disclosures or company-specific news.

Evidence & confidence

The filing is primary-source and specific (shares, price, date), but it is an insider/owner transaction without accompanying operational or guidance changes.

Market effects

No clear sector read-through; this is company-specific ownership activity.

None indicated.

None indicated.

Counterpoint

The purchase may be routine portfolio rebalancing or indirect holdings mechanics rather than a strong bullish thesis.

Key entities

  • Passage BIO, Inc.

    Company whose shares (PASG) were purchased; subject of the Form 4 disclosure.

  • Lynx1 Capital Management LP

    Reporter of the Form 4 transaction; executed an open-market purchase on 2026-06-25.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles